Chronic productive cough is associated with death in smokers with early COPD

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 11, Issue 4, 2014, Pages 451-458

  Putcha, Nirupama ^a   Drummond, M Bradley ^a   Connett, John E ^b   Scanlon, Paul D ^c   Tashkin, Donald P ^d   Hansel, Nadia N ^a   Wise, Robert A ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c MAYO CLINIC   (United States)

^d UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lung function.; Subtypes; Survival; Symptoms

Indexed keywords

ADULT; ARTICLE; CHRONIC COUGH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DEATH; DISEASE SEVERITY; FEMALE; FORCED EXPIRATORY VOLUME; HUMAN; LUNG FUNCTION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RACE; RANDOMIZED CONTROLLED TRIAL; SMOKING; SURVIVAL; CLINICAL TRIAL; COUGH; LONGITUDINAL STUDY; MUCOCILIARY CLEARANCE; MUCUS; PATHOPHYSIOLOGY; RISK FACTOR; SURVIVAL RATE;

ADULT; COUGH; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUCOCILIARY CLEARANCE; MUCUS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RISK FACTORS; SMOKING; SURVIVAL RATE;

EID: 84904212890     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.3109/15412555.2013.837870     Document Type: Article

References (39)

1. Miravitlles M. Cough and sputum production as risk factors for poor outcomes in patients with COPD. Respir Med 2011; 105(8):1118-1128.
2. Lundb?k B, Lindberg A, Lindstr? M, R?mark E, Jonsson AC, J?sson E, Larsson LG, Andersson S, Sandstr? T, Larsson K. Obstructive Lung Disease in Northern Sweden Studies.: Not 15 but 50% of smokers develop COPD?-Report from the Obstructive Lung Disease in Northern Sweden Studies. Respir Med 2003; 97(2):115-122.
3. Voll-Aanerud M, Eagan TM, Plana E, Omenaas ER, Bakke PS, Svanes C, Siroux V, Pin I, Ant?JM, Leynaert B. Respiratory symptoms in adults are related to impaired quality of life, regardless of asthma and COPD: results from the European community respiratory health survey. Health Qual Life Outcomes 2010; 8:107.
4. Kim V, Han MK, Vance GB, Make BJ, Newell JD, Hokanson JE, Hersh CP, Stinson D, Silverman EK, Criner GJ. COPDGene Investigators: The chronic bronchitic phenotype of COPD: an analysis of the COPDGene study. Chest 2011; 140(3):626-633.
5. Burgel PR, Nesme-Meyer P, Chanez P, Caillaud D, Carr?P, Perez T, Roche N. Initiatives Bronchopneumopathie Chronique Obstructive Scientifi c Committee: Cough and sputum production are associated with frequent exacerbations and hospitalizations in COPD subjects. Chest 2009; 135(4):975-982.
6. Vollmer WM, McCamant LE, Johnson LR, Buist AS. Respiratory symptoms, lung function, and mortality in a screening center cohort. Am J Epidemiol 1989; 129(6):1157-1169.
7. Hewitt J, Smeeth L, Bulpitt CJ, Tulloch AJ, Fletcher AE. Respiratory symptoms in older people and their association with mortality. Thorax 2005; 60(4):331-334.
8. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J 1995; 8(8):1333-1338.
9. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45(8):579-585.
10. Hogg JC, Chu FS, Tan WC, Sin DD, Patel SA, Pare PD, Martinez FJ, Rogers RM, Make BJ, Criner GJ, Cherniack RM, Sharafkhaneh A, Luketich JD, Coxson HO, Elliott WM, Sciurba FC. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights from small airway pathology. Am J Respir Crit Care Med 2007; 176(5):454-459.
11. Speizer FE, Fay ME, Dockery DW, Ferris BG Jr. Chronic obstructive pulmonary disease mortality in six US cities. Am Rev Respir Dis 1989; 140:S49-S55.
12. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax 2003; 58:388-393.
13. Fletcher C, Peto R, Tinker C, Speizer FE. The natural history of chronic bronchitis and emphysema. New York/Toronto: Oxford University Press; 1976.
14. Tockman MS, Comstock GW. Respiratory risk factors and mortality: longitudinal studies in Washington County, Maryland. Am Rev Respir Dis 1989; 140:S56-S63.
15. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Th irty-year cumulative incidence of chronic bronchitis and COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest 2006; 130(4):1129-1137.
16. Kim V, Criner GJ. Chronic bronchitis and chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(3):228-237.
17. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5):1530-1535.
18. Guerra S, Sherrill DL, Verker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts incident airfl ow limitation and mortality risk. Thorax 2009; 64:894-900.
19. Sherman CB, Xu X, Speizer FE, Ferris BG Jr, Weiss ST, Dockery DW. Longitudinal lung function decline in subjects with respiratory symptoms. Am Rev Respir Dis 1992; 146(4):855-859.
20. Bridevaux PO, Gerbase MW, Probst-Hensch NM, Schindler C, Gaspoz JM, Rochat T. Long-term decline in lung function, utilisation of care and quality of life in modifi ed GOLD stage 1 COPD. Thorax 2008; 63(9):768-774.
21. de Marco R, Accordini S, Anto JM, Gislason T, Heinrich J, Janson C, et al.: Long-term outcomes in mild/moderate chronic obstructive pulmonary disease in the European community respiratory health survey. Am J Respir Crit Care Med 2009; 180:956-963.
22. Anthonisen NR. Lung Health Study. Am Rev Respir Dis 1989; 140:871-872.
23. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, Conway WA, Jr., Enright PL, Kanner RE, O'Hara P et al. Eff ects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272:1497-1505.
24. Connett JE, Kusek JW, Bailey WC, O'Hara P, Wu M. Design of the Lung Health Study: a randomized clinical trial of early intervention for chronic obstructive pulmonary disease. Control Clin Trials 1993; 14:3S-19S.
25. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The eff ects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005; 142:233-239.
26. Anthonisen NR, Connett JE, Murray RP. Smoking and lung function of Lung Health Study participants after 11 years. Am J Respir Crit Care Med 2002; 166:675-679.
27. Fletcher CM, Peto R, Tinker C. A comparison of the assessment of simple bronchitis (chronic mucus hypersecretion) by measurements of sputum volume and by standardized questions on phlegm production. Int J Epidemiol 1974 Dec; 3(4):315-319.
28. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54:581-586.
29. Enright PL, Johnson LR, Connett JE, Voelker H, Buist AS. Spirometry in the Lung Health Study.
30. Drummond MB, Hansel NN, Connett JE, Scanlon PD, Tashkin DP, Wise RA. Spirometric predictors of lung function decline and mortality in early chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012; 185(12):1301-1306.
31. StataCorp. Stata Statistical Software: Release 12. College Station, TX: StataCorp LP, 2011.
32. Buist AS, Connett JE, Miller RD, Kanner RE, Owens GR, Voelker HT. Chronic Obstructive Pulmonary Disease Early Intervention Trial (Lung Health Study). Baseline characteristics of randomized participants. Chest 1993; 103(6):1863-1872.
33. Puhan MA, Garcia-Aymerich J, Frey M, ter Riet G, Antó JM, Agust?AG, G?ez FP, Rodr?uez-Rois? R, Moons KG, Kessels AG, Held U. Expansion of the prognostic assessment of patients with chronic obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009 Aug; 374(9691):704-711.
34. Celli B, Cote C, Marin J, Casanova C, Montes de Oca M, Mendez R, Pinto-Plata V, Cabral H. The body-mass index, airfl ow obstruction, dyspnea, and exercise capacity index in chronic obstructive pulmonary disease. N Eng J Med 2004; 350:1005-1012.
35. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care. Thorax 2000; 55:635-642.
36. Patel IS, Vlahos I, Wilkinson TM, Lloyd-Owen SJ, Donaldson GC, Wilks M, et al. Bronchiectasis, exacerbation indices, and infl ammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170:400-407.
37. Smith IE, Jurriaans E, Diederich S, Ali N, Shneerson JM, Flower CD. Chronic sputum production: correlations between clinical features and fi ndings on high resolution computed tomographic scanning of the chest. Thorax 1996; 51:914-918.
38. Hurst JR, Vestbo J, Anzueto A, Locantore N, M?lerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA. Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med 2010; 363(12):1128-1138.
39. St?nescu D, Sanna A, Veriter C, Kostianev S, Calcagni PG, Fabbri LM, Maestrelli P. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers are associated with increased levels of sputum neutrophils. Thorax 1996; 51(3):267-271.